Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and ...
The heme program, particularly the TSC-100/101 study ... This demonstrates strong efficacy and safety, distinguishing the program’s outcomes from the control group. Furthermore, the anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback